DLAT (Dihydrolipoamide S-Acetyltransferase) encodes the E2 component of the pyruvate dehydrogenase complex (PDC), a critical metabolic enzyme linking glycolysis to the TCA cycle. This gene has garnered significant attention in neurodegenerative disease research due to the central role of glucose metabolism in neuronal function and the well-documented cerebral hypometabolism in Alzheimer's disease[1][2].
| Dihydrolipoamide S-Acetyltransferase | |
|---|---|
| Gene Symbol | DLAT |
| Full Name | Dihydrolipoamide S-Acetyltransferase |
| Chromosome | 11q23.1 |
| NCBI Gene ID | [1737](https://www.ncbi.nlm.nih.gov/gene/1737) |
| OMIM | 608770 |
| Ensembl ID | ENSG00000150768 |
| UniProt ID | [P10515](https://www.uniprot.org/uniprot/P10515) |
| Protein Class | Metabolic Enzyme (E2 Component) |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), Pyruvate Dehydrogenase Deficiency, Diabetes |
DLAT is the central structural and catalytic component of the pyruvate dehydrogenase complex, forming a 24-mer cubic core that organizes the entire complex[3]. The complex consists of three main enzymatic components: E1 (pyruvate dehydrogenase, encoded by PDHA1 and PDHB), E2 (DLAT), and E3 (dihydrolipoamide dehydrogenase, encoded by DLD), along with regulatory enzymes E3BP and PDK. This multi-enzyme complex is embedded in the mitochondrial matrix and is essential for cellular energy production through aerobic respiration.
The pyruvate dehydrogenase complex catalyzes the oxidative decarboxylation of pyruvate to acetyl-CoA, the rate-limiting step that links glycolysis to the TCA cycle and oxidative phosphorylation. This reaction is fundamental to aerobic energy metabolism, and its dysfunction has profound consequences for cellular energetics, particularly in high-energy-demand tissues like the brain.
The DLAT protein serves dual roles as both the structural scaffold and catalytic engine of the PDC. Each DLAT monomer consists of three distinct domains:
| Domain | Position | Function |
|---|---|---|
| N-terminal lipoyl domain | 1-90 | Contains lipoyllysine for cofactor attachment |
| Peripheral subunit-binding domain | 91-200 | Binds E1 and E3 components |
| C-terminal catalytic domain | 201-647 | Catalyzes acetyl transfer to CoA |
The DLAT protein forms a 24-mer cubic core through dimerization of 12 identical subunits, creating a remarkable architectural feat that positions the catalytic sites optimally for substrate channeling between E1, E2, and E3 components[3:1].
The acetyltransfer reaction proceeds through a series of intermediate steps:
This mechanism ensures efficient substrate channeling without release of intermediate products, maximizing metabolic efficiency.
The lipoylation of DLAT is essential for its function. The lipoic acid cofactor, covalently attached to a lysine residue in the lipoyl domain, serves as a swinging arm that carries acetyl groups between the active sites of E1, E2, and E3. This process requires:
Defects in lipoylation lead to PDC dysfunction and severe metabolic disease[4][5].
Neurons are highly energy-dependent cells requiring continuous ATP production for:
DLAT-mediated PDC activity is the rate-limiting step linking glycolysis to oxidative phosphorylation. In neurons, this process is particularly critical because[6][7]:
The vulnerability of neuronal glucose metabolism to dysfunction makes PDC a critical node in understanding neurodegenerative processes.
DLAT variants and expression changes are associated with several conditions:
PDC deficiency is one of the most common inherited metabolic disorders of energy metabolism[4:1]:
DLAT shows significant downregulation in AD brains and is implicated in disease pathogenesis through multiple mechanisms[1:1][2:1][8][9]:
Cerebral Hypometabolism:
Amyloid-β Effects:
Tau Pathology:
Therapeutic Implications:
DLAT is expressed throughout the brain with highest levels in regions with high metabolic demand:
| Brain Region | Expression Level | Significance |
|---|---|---|
| Cerebral Cortex | High | High synaptic density, elevated energy demand |
| Hippocampus | High | Memory formation, CA1 especially vulnerable in AD |
| Basal Ganglia | Moderate-High | Motor control, dopaminergic neuron maintenance |
| Cerebellum | High | Motor coordination, Purkinje cells |
| Brainstem | Moderate | Vital functions, cranial nerve nuclei |
| White Matter | Lower | Myelinated axons, lower metabolic activity |
DLAT expression is regulated by:
DLAT interacts with multiple proteins within the mitochondrial metabolic network:
| Protein | Role | Interaction Type |
|---|---|---|
| PDHA1 | E1α (pyruvate dehydrogenase) | Catalytic substrate binding |
| PDHB | E1β | Forms heterotetramer with PDHA1 |
| DLAT | Self | Forms 24-mer core through dimerization |
| DLD | E3 (dihydrolipoamide dehydrogenase) | Electron transfer |
| PDHX | E3BP | Alternative E3 binding protein |
| PDP1/PDP2 | Phosphatases | Regulatory dephosphorylation |
| PDK1/PDK2/PDK3 | Kinases | Regulatory phosphorylation |
These interactions coordinate the metabolic flux through the PDC, with kinase/phosphatase regulation providing rapid control of PDC activity in response to cellular energy demands[9:1][12].
DLAT activity is regulated at multiple levels:
| Modification | Effect | Enzyme |
|---|---|---|
| Phosphorylation | Inhibits PDC activity | PDK1/2/3 |
| Dephosphorylation | Activates PDC | PDP1/2 |
| Lipoylation | Essential for catalytic function | LPL family |
| Acetylation | Metabolic regulation | Acetyltransferases |
Given the central role of DLAT in cellular metabolism, several therapeutic strategies are being explored[10:1][5:1][11:1]:
The ketogenic diet bypasses PDC by providing alternative fuel:
DLAT and brain metabolism in Alzheimer's disease. J Neurosci. 2010. ↩︎ ↩︎
Cerebral metabolic deficiencies in Alzheimer's disease. J Alzheimers Dis. 2010. ↩︎ ↩︎
Pyruvate dehydrogenase complex: structure and function. J Mol Biol. 2014. ↩︎ ↩︎
Pyruvate dehydrogenase deficiency: clinical features and treatment. Mitochondrion. 2012. ↩︎ ↩︎
Lipoic acid supplementation: effects on mitochondrial function. J Nutr Biochem. 2011. ↩︎ ↩︎
Metabolic dysfunction in Alzheimer's disease: from mitochondrial dysfunction to therapeutic targets. Cell Death Dis. 2020. ↩︎
Bioenergetics and mitochondrial abnormalities in Alzheimer's disease. Cell Mol Neurobiol. 2013. ↩︎
Early decline in glucose transport and metabolism in Alzheimer's mouse brain. J Alzheimers Dis. 2013. ↩︎
Pyruvate dehydrogenase complex activity and regulation in Alzheimer's disease. Ann Neurol. 2019. ↩︎ ↩︎
Lipoic acid improves cerebral blood flow and cognitive function. Pharmacopsychiatry. 2009. ↩︎ ↩︎
Targeting mitochondrial dysfunction in Alzheimer's disease. Adv Exp Med Biol. 2020. ↩︎ ↩︎
Mitochondrial quality control and mitochondrial biogenesis in Alzheimer's disease. J Alzheimers Dis. 2017. ↩︎